Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments

International Journal of Cancer

Volumn 133, Issue 12, 2013, Pages 2895-2902

  Lee, I Cheng ^a,b   Huang, Yi Hsiang ^a,b   Chau, Gar Yang ^a   Huo, Teh Ia ^a,b   Su, Chien Wei ^a,b   Wu, Jaw Ching ^a,b   Lin, Han Chieh ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

cancer immunology; hepatocellular carcinoma; interferon gamma; recurrence

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; AUTOIMMUNE REGULATOR PROTEIN; BILIRUBIN; CD45RO ANTIGEN; CD69 ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER IMMUNOLOGY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INTERFERON PRODUCTION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; RECURRENT DISEASE; REGULATORY T LYMPHOCYTE; TH17 CELL; TUMOR VOLUME;

CANCER IMMUNOLOGY; HEPATOCELLULAR CARCINOMA; INTERFERON-GAMMA; RECURRENCE;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; INTERFERON-GAMMA; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL;

EID: 84885586265     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28311     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Llovet JM, Burroughs A, Bruix J,. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
3. El-Serag HB,. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-27.
4. Huang YH, Chen CH, Chang TT, et al. The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma: a nation-wide, multicenter study. Liver Int 2004; 24: 419-24.
5. Huang YH, Chen CH, Chang TT, et al. Evaluation of predictive value of CLIP, Okuda, TNM and JIS staging systems for hepatocellular carcinoma patients undergoing surgery. J Gastroenterol Hepatol 2005; 20: 765-71.
6. Finn OJ,. Cancer immunology. N Engl J Med 2008; 358: 2704-15.
7. Schreiber RD, Old LJ, Smyth MJ,. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-70.
8. Vesely MD, Kershaw MH, Schreiber RD, et al. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29: 235-71.
9. Korangy F, Hochst B, Manns MP, et al. Immunotherapy of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2010; 4: 345-53.
10. Breous E, Thimme R,. Potential of immunotherapy for hepatocellular carcinoma. J Hepatol 2011; 54: 830-4.
11. Hernandez-Gea V, Toffanin S, Friedman SL, et al. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 2013; 144: 512-27.
12. Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132: 2328-39.
13. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007; 25: 2586-93.
14. Zhang JP, Yan J, Xu J, et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009; 50: 980-9.
15. Wu J, Du J, Liu L, et al. Elevated pretherapy serum IL17 in primary hepatocellular carcinoma patients correlate to increased risk of early recurrence after curative hepatectomy. PLoS One 2012; 7: e50035.
16. Tatsumi T, Takehara T, Yamaguchi S, et al. Intrahepatic delivery of alpha-galactosylceramide-pulsed dendritic cells suppresses liver tumor. Hepatology 2007; 45: 22-30.
17. Wherry EJ,. T cell exhaustion. Nat Immunol 2011; 12: 492-9.
18. Watanabe T, Bertoletti A, Tanoto TA,. PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection. J Viral Hepat 2010; 17: 453-8.
19. Gao Q, Wang XY, Qiu SJ, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009; 15: 971-9.
20. Shi F, Shi M, Zeng Z, et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 2011; 128: 887-96.
21. Budhu A, Wang XW,. The role of cytokines in hepatocellular carcinoma. J Leukoc Biol 2006; 80: 1197-213.
22. Chau GY, Wu CW, Lui WY, et al. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg 2000; 231: 552-8.
23. Blobe GC, Schiemann WP, Lodish HF,. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-8.
24. Achyut BR, Yang L,. Transforming growth factor-beta in the gastrointestinal and hepatic tumor microenvironment. Gastroenterology 2011; 141: 1167-78.
25. Okumoto K, Hattori E, Tamura K, et al. Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver Int 2004; 24: 21-8.
26. Ikeda H, Old LJ, Schreiber RD,. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002; 13: 95-109.
27. Horras CJ, Lamb CL, Mitchell KA,. Regulation of hepatocyte fate by interferon-gamma. Cytokine Growth Factor Rev 2011; 22: 35-43.
28. Sonneveld MJ, Arends P, Boonstra A, et al. Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B. J Hepatol 2013; 58: 898-903.
29. Lagging M, Romero AI, Westin J, et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 2006; 44: 1617-25.
30. Lee IC, Lin CH, Huang YH, et al. IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B. PLoS One 2013; 8: e58071.
31. Bruix J, Sherman M,. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
32. Bruix J, Sherman M,. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
33. Huang YH, Tao MH, Hu CP, et al. Identification of novel HLA-A0201-restricted CD8+ T-cell epitopes on hepatitis delta virus. J Gen Virol 2004; 85: 3089-98.
34. Kalathil S, Lugade AA, Miller A, et al. Higher frequencies of GARP+CTLA-4+Foxp3+ T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-Cell functionality. Cancer Res 2013; 73: 2435-44.
35. Parekh VV, Lalani S, Kim S, et al. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J Immunol 2009; 182: 2816-26.
36. Huitzil-Melendez FD, Capanu M, O'Reilly EM, et al. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol 2010; 28: 2889-95.
37. Li P, Du Q, Cao Z, et al. Interferon-gamma induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (HCC) cells through interferon-regulatory factor-1 (IRF-1). Cancer Lett 2012; 314: 213-22.
38. Zhu J, Feng A, Sun J, et al. Increased CD4(+) CD69(+) CD25(-) T cells in patients with hepatocellular carcinoma are associated with tumor progression. J Gastroenterol Hepatol 2011; 26: 1519-26.
39. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353: 2654-66.
40. Fu J, Zhang Z, Zhou L, et al. Impairment of CD4(+) cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology, in press. doi: 10.1002/hep.26054.
41. Reinisch W, Holub M, Katz A, et al. Prospective pilot study of recombinant granulocyte-macrophage colony-stimulating factor and interferon-gamma in patients with inoperable hepatocellular carcinoma. J Immunother 2002; 25: 489-99.
42. Lygidakis NJ, Kosmidis P, Ziras N, et al. Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem. J Interferon Cytokine Res 1995; 15: 467-72.